Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee

NCT: NCT07332182 · RECRUITING

NCT IDNCT07332182
StatusRECRUITING
Start Date2026-09
Completion2031-04-30
SponsorFin-Ceramica Faenza Spa (INDUSTRY)
First posted
Last updated

Brief Summary

The present study aims to compare the efficacy and the safety of MaioRegen Prime to Debridement (SSOC) in patients with deep osteochondral lesions of the knee joint. The foreseen population involves patients with osteochondral lesions with different etiology, dimension, shape, and location. The evaluation will be performed through clinical, subjective and objective assessments.

Frequently Asked Questions

What is MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee?

MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee is a clinical trial registered under NCT07332182. Current status: RECRUITING.

What is the status of NCT07332182?

The current status of NCT07332182 (MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee) is: RECRUITING.

When did MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee start?

MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee started on 2026-09.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.